Predict S.P.A. Class B
MMIL:PRE0.91
EUR
0.00
(0.00%)
ISIN
IT0005611071
Return %
Stock
S&P 500
1Y
8.98
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Angelo Aurelio Gigante
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Bari Italy
- IPO Date
- Sep 26, 2024
- Website
- predictcare.it
- Similar Companies
- Business
- Predict S.p.A. is an Italy-based healthcare technology company that specializes in the distribution of in vivo diagnostic imaging systems, the development of non-invasive breath analysis technologies for disease screening, and the provision of digital healthcare solutions integrating artificial intelligence, robotics, and augmented reality. Founded in 2008 and headquartered in Bari, Italy, with additional operational offices in Milan and Rome, the company serves public hospitals, private healthcare facilities, diagnostic centers, and academic research institutions across Italy and select international markets. The company operates through four core strategic business units: Imaging, People Support, Mistral, and Digital Healthcare. Predict S.p.A. provides an integrated portfolio of medical products and clinical services, comprising: the authorized commercial distribution, installation, and technical maintenance of advanced in vivo diagnostic imaging systems, including ultrasound equipment, radiological X-ray systems, and magnetic resonance imaging (MRI) devices, primarily supplied through an established long-term partnership with GE HealthCare; specialized clinical, technical, and operational assistance services for radiology and ultrasound departments through its People Support division; proprietary breath analysis screening platforms under the Mistral brand, which utilize specialized breath samplers and thermal desorption-gas chromatography-mass spectrometry (TD-GC-MS) laboratory workflows to analyze volatile organic compounds (VOCs) for early, non-invasive screening of oncological diseases and other pathologies; artificial intelligence-powered service and humanoid robotics platforms under the Aphel brand, including the Aphel Helios, Aphel Hermes, and Aphel Kronos units, configured for hospital reception, patient accompaniment, anamnesis data collection, and clinical education; and holographic telepresence and augmented reality systems under the Optip brand, including Optip Stage, engineered for remote medical consultations, surgical proctoring, interactive medical training, and virtual collaborative healthcare environments. In recent developments, Predict S.p.A. completed its initial public offering (IPO) and commenced trading of its Class B ordinary shares on the Euronext Growth Milan market organized and managed by Borsa Italiana in September 2024 under the ticker symbol PRE, raising approximately 1.6 million euros in growth capital to fund proprietary technology research, scale its digital health platforms, and pursue international market expansion. The company established a capital structure incorporating publicly listed Class B shares alongside unlisted multiple-voting shares and performance-contingent Price Adjustment Shares (PAS). In addition, the company expanded its commercial robotics offering through a national distribution agreement in Italy for temi autonomous service robots developed by Robocore, launched the collaborative IAUSO research initiative to integrate artificial intelligence algorithms into fetal ultrasound diagnostics alongside the Policlinico di Bari, advanced clinical validation studies for its Mistral breath analysis technology in partnership with academic institutions including the University of Bari, and implemented corporate equity incentive programs including share buyback authorizations and stock grant plans.